PharmacyCodes



Balsalazido [Spanish] en es it fr

Balsalazido [Spanish] Brand names, Balsalazido [Spanish] Analogs

Balsalazido [Spanish] Brand Names Mixture

  • No information avaliable

Balsalazido [Spanish] Chemical_Formula

C17H15N3O6

Balsalazido [Spanish] RX_link

http://www.rxlist.com/cgi/generic2/balsalazide.htm

Balsalazido [Spanish] fda sheet

Balsalazido_[Spanish] FDA

Balsalazido [Spanish] msds (material safety sheet)

Balsalazido [Spanish] Synthesis Reference

No information avaliable

Balsalazido [Spanish] Molecular Weight

357.318 g/mol

Balsalazido [Spanish] Melting Point

No information avaliable

Balsalazido [Spanish] H2O Solubility

Freely soluble as disodium salt

Balsalazido [Spanish] State

Solid

Balsalazido [Spanish] LogP

2.417

Balsalazido [Spanish] Dosage Forms

Capsule (750 mg)

Balsalazido [Spanish] Indication

For the treatment of mildly to moderately active ulcerative colitis.

Balsalazido [Spanish] Pharmacology

Balsalazide is a prodrug that is enzymatically cleaved in the colon to produce mesalamine (5-aminosalicylic acid), an anti inflammatory drug indicated for the treatment of mildly to moderately active ulcerative colitis. Balsalazide disodium is delivered intact to the colon where it is cleaved by bacterial azoreduction to release equimolar quantities of mesalamine, which is the therapeutically active portion of the molecule, and 4-aminobenzoyl-(beta)-alanine.

Balsalazido [Spanish] Absorption

Low and variable, intact balsalazide is poorly absorbed systemically.

Balsalazido [Spanish] side effects and Toxicity

A single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.

Balsalazido [Spanish] Patient Information

No information avaliable

Balsalazido [Spanish] Organisms Affected

Humans and other mammals